Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022 - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

Nareg Sagherian ,Karen Preble ,Krisv Kowdley ,Washington State University ,Linkedin ,Twitter ,Komodo Health ,Elsons Floyd College Of Medicine ,Nasdaq ,Liver Institute ,Global Corporate Communications ,Intercept Pharmaceuticals Inc ,Liver Meeting ,American Association ,Liver Diseases ,Obeticholic Acid ,External Control ,Clinical Outcomes ,Primary Biliary Cholangitis ,Original Primary Composite Endpoint ,Primary Endpoint ,Treatment Efficacy ,Hepatic Real World Outcomes ,Liver Institute Northwest ,Washington State ,Social Security Death Index ,Executive Director ,Global Investor ,Global Corporate ,Resume ,Careers ,Ntercept Announces Two Analyses Demonstrating Improvement In Outcomes ,Ncluding Transplant Free Survival ,Or Pbc Patients Treated With Oca To Be Presented At Aasld The Liver Meeting 2022 ,Iospace ,Advice ,